drug_type
RELEVANT_DRUG
intervention_type
cellular therapy (CAR-NK cell)
drug_description
Allogeneic NK-92–derived CAR-NK cell therapy engineered to recognize PD-L1 and express high-affinity CD16 (FcγRIIIa) for direct tumor killing and enhanced ADCC.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic NK-92–derived CAR-NK engineered with a PD-L1–targeting CAR to directly recognize and kill PD-L1–expressing tumor cells, and co-expressing high-affinity CD16 (FcγRIIIa) to mediate robust antibody-dependent cellular cytotoxicity (ADCC) in the presence of IgG1 therapeutic antibodies (e.g., cetuximab).
drug_name
PD-L1 t-haNK
nct_id_drug_ref
NCT06239220